Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Multicenter, Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

NCT05647954 is registered in ClinicalTrials.gov with Taizhou Hanzhong biomedical co. LTD as lead sponsor.

NCT NCT05647954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05647954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Multicenter, Phase III Study of HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2022
Completion date
June 30, 2025
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma neuroendocrine tumors neuroectodermal tumors neoplasms germ cell and embryonal neoplasms by histologic type neoplasms neoplasms